Q-omics provides the consensus-scored KAT2A profile across patient tissues and cancer cell-line models. KAT2A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KAT2A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, KAT2A protein abundance shows 27,182 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where KAT2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KAT2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KAT2A survival associations across molecular data types. KAT2A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KAT2A RNA expression–survival associations across cancer types. High KAT2A expression shows unfavorable associations in KIRC, ACC, LIHC, UVM and KICH, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KAT2A RNA expression.
This table summarizes KAT2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KAT2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KAT2A shows higher tumor expression in HNSC, COAD, LIHC, STAD, LUAD and BLCA. The HNSC box plot shows higher KAT2A RNA expression in tumor versus normal tissue (log2 FC = +1.177, t-test p < 0.001).
This table shows molecular features associated with KAT2A in patient tissues and cancer cell lines. In patient samples, KAT2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KAT2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
